Indian court sets 3-parameter format for trial applicants
This article was originally published in Scrip
India's Supreme Court has ordered the specific inclusion of three parameters when seeking information from applicants for trials in India. They are the assessment of risk versus benefit to the patients, innovation vis-à-vis existing therapeutic option, and unmet medical need in the country.
You may also be interested in...
India's clinical research segment has had a rough time of late. Uncertainties, evolving regulations and compliance deviations have hurt the sector that is now scarred with firms downing the shutter, mistrust and constant speculation. Scrip spoke to a number of CROs who appear to have weathered the storm, but it seems the industry may not be out of the woods just yet.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?